ABG
OVID icon

Ally Bridge Group’s Ovid Therapeutics OVID Stock Holding History

Ally Bridge Group’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.68M Sell
624,561
-2,193,898
-78% -$5.66M 1.49% 22
2026
Q1 		$6.26M Buy
2,818,459
+1,033,459
+58% +$1.85M 5.05% 5
2025
Q4 		$2.91M Buy
+1,785,000
New +$2.75M 3.03% 13

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Ally Bridge Group's OVID Position: Q2 2026 in Review

Ally Bridge Group reduced its Ovid Therapeutics (OVID) stake by 78% in Q2 2026, selling an estimated $5.66M and leaving 624,561 shares worth $1.68M. The position accounts for 1.49% of the portfolio, ranked #22.

Ally Bridge Group first reported a position in OVID in Q4 2025 and has held it in 3 quarters since. The position peaked at $6.26M in Q1 2026. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • Ally Bridge Group held 624,561 shares of Ovid Therapeutics worth $1.68M as of Q2 2026.
  • Ally Bridge Group sold 2,193,898 Ovid Therapeutics shares in Q2 2026, an estimated $5.66M.
  • Ovid Therapeutics made up 1.49% of Ally Bridge Group's portfolio in Q2 2026, its #22 holding.
  • Ally Bridge Group first reported a position in Ovid Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Ally Bridge Group's Ovid Therapeutics position peaked at $6.26M in Q1 2026.
  • 131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on Ally Bridge Group's 13F filing for Q2 2026, filed 14 Aug 2026.